Clinical trial · Interventional
Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab
Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab - Phase 2
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 26, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260926-000001
Summary
Brief summary (as posted)
The main goal of this study is to test a virtual reality (VR) program, Survivors' Virtual Reality Survivorship Experience (SurviVRSE), designed to help Breast Cancer survivors (n=30) learn about heart health. The aims are to test the usability, feasibility, and acceptability o the intervention. Additionally, follow-up assessments will examine changes in women's cancer therapy related cardiac dysfunction knowledge and heart healthy behaviors (e.g., physical activity).
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anthracycline Related Cardiotoxicity in Breast Cancer | Breast Neoplasm | PROBABILISTIC | 0.70 |
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Trastuzumab | — | UNRESOLVED | — |
| Virtual Reality | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cardiovascular Health Education and Gaming through Virtual Reality | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Virtual Reality Group
- description
- Individuals in this arm will receive access to the virtual reality in cardiovascular health education and gaming intervention
- interventionNames
- Behavioral: Cardiovascular Health Education and Gaming through Virtual Reality
Primary outcomes (4)
- measure
- CTRCD Knowledge
- timeFrame
- Baseline, within 2 days post-Intervention, and 4 weeks post-intervention
- description
- Change in knowledge of CTRCD and in measures of improving cardiovascular health. This investigator-developed true/false knowledge survey consists of 10 items that directly assess knowledge learned in SurviVRSE. Scoring this scale will consist of summing up the total items that were answered correctly (range = 0-10; 0 = no knowledge and 10=high knowledge).
- measure
- Usability
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 18 years of age or older * Able to speak and read in English * Actively receiving Trastuzumab or an anthracycline-based treatment * Currently receiving immunotherapy. This includes pembrolizumab and atezolizumab. * Diagnosed with stages 0-III Breast Cancer Exclusion Criteria: \- History of prior Breast Cancer diagnosis (i.e., not their first breast cancer diagnosis)
References
Publications (0)
Data not yet available